Sara Revolinski, PharmD, BCPS
Residency Program Director - PGYI Community-Based Residency Program, Assistant Professor Department of Clinical Sciences
Locations
- MCW Pharmacy School
HRC H2600
Contact Information
Education
Post Graduate Year One (PGY-1) Pharmacy Practice Residency, Froedtert Hospital
Certifications
Board Certified Pharmacotherapy Specialist (BCPS), Board of Pharmacy Specialties
Antimicrobial Stewardship Certificate, Society of Infectious Diseases Pharmacists
Registered Pharmacist: Wisconsin
Biography
Research Interests
- Antimicrobial stewardship outcomes research
- Rapid diagnostic technology and its impact on antimicrobial stewardship
- Pharmacokinetics and pharmacodynamics of antimicrobial agents
- Clostridium difficile and other multidrug-resistant infections
Publications
-
Fecal Microbiota Transplantation for Clostridioides difficile Infection in Immunocompromised Hosts.
(Revolinski S, Munoz-Price LS.) Clin Infect Dis. 2021 Jun 15;72(12):2247 PMID: 32275059 SCOPUS ID: 2-s2.0-85103344088 04/11/2020
-
Point-Counterpoint: Should Clinical Microbiology Laboratories Report Vancomycin MICs?
(Revolinski SL, Doern CD.) J Clin Microbiol. 2021 Mar 19;59(4) PMID: 33536296 PMCID: PMC8092730 SCOPUS ID: 2-s2.0-85102931996 02/05/2021
-
Impact of an Antimicrobial Stewardship Program Pharmacist During Microbiology Rounds.
(Sapozhnikov J, Huang A, Revolinski S, Ledeboer NA, Buchan BW.) Am J Clin Pathol. 2021 Feb 11;155(3):455-460 PMID: 32949141 SCOPUS ID: 2-s2.0-85102099001 09/20/2020
-
(Zein Eddine SB, Cooper-Johnson K, Ericksen F, Brookes CC, Peppard WJ, Revolinski SL, Carver TW.) J Surg Res. 2020 Mar;247:524-529 PMID: 31668431 SCOPUS ID: 2-s2.0-85074440328 11/02/2019
-
Clostridioides difficile in transplant patients: early diagnosis, treatment, and prevention.
(Revolinski SL, Munoz-Price LS.) Curr Opin Infect Dis. 2019 Aug;32(4):307-313 PMID: 31116134 SCOPUS ID: 2-s2.0-85069234375 05/23/2019
-
(Revolinski SL, Munoz-Price LS.) Clin Infect Dis. 2019 May 30;68(12):2144-2153 PMID: 30281082 SCOPUS ID: 2-s2.0-85064842624 10/04/2018
-
(Lat I, Daley MJ, Shewale A, Pangrazzi MH, Hammond D, Olsen KM, DEFINE study group and the Discovery Research Network.) Pharmacotherapy. 2019 Mar;39(3):253-260 PMID: 30101412 SCOPUS ID: 2-s2.0-85054312441 08/14/2018
-
Clostridium difficile Exposures, Colonization, and the Microbiome: Implications for Prevention.
(Revolinski SL, Munoz-Price LS.) Infect Control Hosp Epidemiol. 2018 May;39(5):596-602 PMID: 29553000 SCOPUS ID: 2-s2.0-85044227070 03/20/2018
-
(Foolad F, Huang AM, Nguyen CT, Colyer L, Lim M, Grieger J, Li J, Revolinski S, Mack M, Gandhi T, Wainaina JN, Eschenauer G, Patel TS, Marshall VD, Nagel J.) J Antimicrob Chemother. 2018 May 01;73(5):1402-1407 PMID: 29462306 SCOPUS ID: 2-s2.0-85047020330 02/21/2018
-
Rapid diagnostics in infection prevention
(Revolinski S, Huang AM, Gibble A.) Infection Prevention: New Perspectives and Controversies. 7 September 2017:297-305 SCOPUS ID: 2-s2.0-85034761271 09/07/2017
-
(Revolinski S.) Antibiotics. 21 December 2015;4(4):667-674 SCOPUS ID: 2-s2.0-85007147464 12/21/2015
I strongly believe education and life-long learning is at the core of successful pharmacy practice. Beyond teaching foundational knowledge, I also focus on promoting open communication, critical thinking and reasoning, and engaging learners to take ownership of education. I believe teaching these skills will develop pharmacy practitioners who are well positioned to positively impact the health of our community throughout their careers.
Sara Revolinski, PharmD, BCPS